Celiac Disease Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | 9 Metres Biopharma, Takeda, Zedira, Allero, ActoBio, Amgen, Amyra, Anokion

 Breaking News
  • No posts were found

Celiac Disease Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | 9 Metres Biopharma, Takeda, Zedira, Allero, ActoBio, Amgen, Amyra, Anokion

Celiac Disease Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | 9 Metres Biopharma, Takeda, Zedira, Allero, ActoBio, Amgen, Amyra, Anokion
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Celiac Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Celiac Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Celiac Disease Market. 

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Celiac Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Celiac Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Celiac Disease Pipeline Analysis

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Celiac Disease Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Celiac Disease Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Mechanism of Action of the Emerging Pipeline Therapies 

  • Cell membrane permeability inhibitors

  • Interleukin 15 inhibitors

  • Immunomodulators

Learn How the Ongoing Clinical & Commercial Activities will Affect the Celiac Disease Therapeutic Segment @


Celiac Disease Therapeutics Landscape

There are approx. 25+ key companies which are developing therapies for Celiac Disease. Currently,  9 Meters Biopharma is leading the therapeutics market with its Celiac Disease drug candidates in the most advanced stage of clinical development.

The Leading Players in the Celiac Disease Therapeutics Market Include:

  • 9 Metres Biopharma

  • ActoBio Therapeutics

  • Amgen

  • Amyra biotech

  • Anokion

  • Calypso Biotech

  • GlaxoSmithKline

  • ImmunogenX

  • ImmusanT

  • Millennium Pharmaceuticals

  • Takeda

  • Zedira GmbH

  • Allero Therapeutics

And Many Others

Celiac Disease Emerging and Marketed Drugs Covered in the Report Include:

  • AG017: Precigen ActoBio

  • ALL-001: Allero Therapeutics

  • AMG-714/PRV-015: Amgen

  • BNZ-2: Bioniz

  • CALY 002: Calypso Biotech

  • CNP- 101: Cour Pharmaceutical

  • KAN 101: Anokion

  • Larazotide Acetate (INN-202/AT-1001): 9 Meters Biopharma

  • Latiglutenase (IMGX003/ALV003): ImmunogenX

  • Ordesekimab – Amgen

  • PRV-015: Provention Bio

  • TAK-101: Takeda/Cour Pharmaceuticals

  • ZED1227: Falk Pharma and Zedira

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Celiac Disease Current Treatment Patterns

4. Celiac Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Celiac Disease Late Stage Products (Phase-III)

7. Celiac Disease Mid-Stage Products (Phase-II)

8. Celiac Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Celiac Disease Discontinued Products

13. Celiac Disease Product Profiles

14. Key Companies in the Celiac Disease Market

15. Key Products in the Celiac Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Celiac Disease Unmet Needs

18. Celiac Disease Future Perspectives

19. Celiac Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Breast Pumps Market

The global Breast Pumps Market was valued at USD 1,081.96 million in 2021, growing at a CAGR of 8.67% during the forecast period (2023-2028); it is expected to reach USD 1,776.50 million by 2028. The Breast Pumps Market is witnessing positive growth owing to various key factors such as the surge in the number of employed mothers, technological advancements in the product offering, changes in consumer lifestyle, and increasing awareness for breast pumps thereby, among others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/